You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Covid-19: Maharashtra govt says Molnupiravir must be used with caution

'Till further clarity is received, you are requested to please use Molnupiravir with abundant caution and in certain conditions and that also in full advised dose'

Maharashtra | Coronavirus

Press Trust of India  |  Pune 

Covid treatment pill Molnupiravir (Photo: Reuters)
Covid treatment pill Molnupiravir (Photo: Reuters)

The government on Monday issued a letter to the district, civic administrations and health departments in the state asking them to use oral anti-viral drug 'Molnupiravir' for treatment of symptomatic, adult COVID-19 patients with "abundant caution and in certain conditions".

Dr Pradeep Vyas, additional chief secretary (health), in the letter, requested district and civic authorities to use Molnupiravir with "abundant caution and in certain conditions and in full advised dose". He said this drug has received emergency use authorization (from the Drug Controller General of India) and based on the opinion of some experts it has also been included in treatment protocol circulated on January 6, 2022, in the state subject to certain conditions.

"Subsequently, certain state governments like Odisha have withdrawn this drug from the market. ICMR has also not recommended its use in the treatment of SARS-CoV-2 infection (which causes COVID-19). Molnupiravir has not been included in the Standard Treatment Protocol released by the Government of India on January 17, 2022," Dr Vyas said in the letter. Molnupiravir has been shown to reduce hospitalization in a clinical trial and thus has received emergency use authorization, not an FDA approval, the letter stated.

"Till further clarity is received, you are requested to please use Molnupiravir with abundant caution and in certain conditions and that also in full advised dose," the senior bureaucrat stated. The letter-cum advisory said the drug may be "prescribed for the treatment of COVID-19 in patients who have mild illness not requiring oxygen, one or more risk factors that will cause hospitalization and impending severe disease, in whom there are no other options available, where there are no contra-indications to the use of Molnupiravir' and in the first five days of the illness".

However, patients under the age of 18 and pregnant women should not be given this drug, it maintained. Besides district and civic heads and health departments, the letter has been marked to district civil surgeons and health officers.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, January 18 2022. 01:10 IST